Impressively, the authors proposed a different therapeutic conjugation of pancreatic cancer-specific 2’-fluoropyrimidine RNA-aptamers and C/EBPα-small activating RNA, which accounted for the inhibition of pancreatic cancer growth [106]. The gene discussed is CEBPA; the disease is familial pancreatic carcinoma.